Avanos Medical, Inc. (AVNS) — ESG & Values Scores

Environment story

Avanos Medical discloses minimal environmental data in the 10-K filing. Scope 1, 2, and 3 emissions are not disclosed, resulting in a 15-point deduction. No net-zero target year is stated, triggering a 15-point deduction. The company acknowledges climate-change operational risks (supply chain, facilities, energy costs, raw materials) but provides no quantified mitigation initiatives or decarbonization infrastructure investments. Mexico manufacturing concentration exposes operations to weather and regulatory climate risks. No evidence of greenwashing detected, but substantial disclosure gaps prevent higher scoring.

Criticisms on file

Missing Scope 1, 2, 3 emissions disclosure; no net-zero commitment or target year published
Source: AVNS 10-K Risk Factors; Item 1A climate-change risks section.

Disclosed initiatives

Climate Risk Acknowledgment

Company acknowledges that shifts in weather patterns and climate change increase frequency and severity of adverse conditions, and that climate-related regulations may increase operational and compliance costs.

Awareness only; no quantified mitigation strategy disclosed.

Social story

Avanos Medical provides limited social disclosure in its 10-K. CEO-to-worker pay ratio is not disclosed. No documented union-suppression activities or major strikes within 24 months are evident from the filing. Diversity metrics for leadership and executive teams are not disclosed, preventing assessment against the 30% threshold. Supply-chain human-rights audit data is absent; no specific cobalt, lithium, or conflict-mineral hazard mitigation is described. The company mentions turnover and recruitment challenges as business risks but does not quantify turnover rates or diversity percentages. Restructuring and transformation initiatives may create workforce disruption (noted in Risk Factors) but no labor relations controversies are detailed.

Criticisms on file

No CEO-to-worker pay ratio disclosed; no diversity percentages for executives/board disclosed
Source: AVNS 10-K; compensation and diversity information absent from filing.
No supply-chain human-rights audits or conflict-minerals policies disclosed; manufacturing in Mexico with labor-cost inflation pressures noted
Source: AVNS 10-K Risk Factors; Mexico operations section.
Restructuring initiative (2023–2026) flagged as disruptive to operations and employee morale; potential layoffs and organizational churn not quantified
Source: AVNS 10-K Risk Factors; 'We may not successfully execute on or achieve the expected benefits of our restructuring initiative' section.

Disclosed initiatives

Talent Recruitment & Retention Focus

Company identifies ability to attract and retain qualified executives and employees, particularly those with specialized technical skills, as critical to competitiveness.

Acknowledged risk; no specific programs or metrics disclosed.
Transformation Process Workforce Impact

Restructuring initiated January 2023 includes organizational alignment and cost-management activities expected through 2026. Company acknowledges potential for reduced employee morale during restructuring.

May negatively affect employee retention and engagement; no mitigation measures disclosed.

Governance story

Avanos Medical exhibits mixed governance controls. The 10-K does not disclose board independence percentage; without explicit confirmation of >75%, a 15-point deduction applies. No dual-class share structure with unequal voting rights is identified; single-class common stock assumed. Lobbying spend is not disclosed, preventing assessment of climate-deregulation targeting. The company is not currently subject to active antitrust, consumer-safety, or financial-fraud regulatory proceedings reported in the filing; however, product-liability and recall risks are acknowledged as inherent industry risks. Two goodwill impairment charges ($336.5M in Q4 2024 and $77M in Q2 2025) reflect valuation reassessments but not regulatory sanctions. Anti-takeover provisions (preferred stock authority, supermajority voting, advance notice requirements) are present but standard for Delaware corporations and not penalized under current rubric. No evidence of shareholder climate-proposal litigation or activist shareholder suppression.

Criticisms on file

Board independence percentage not disclosed; unable to verify >75% threshold compliance
Source: AVNS 10-K; board composition and independence data absent from filing.
Lobbying expenditures not disclosed; unable to assess climate-deregulation targeting
Source: AVNS 10-K; lobbying spend not reported.
Substantial goodwill impairment charges ($336.5M Q4 2024; $77M Q2 2025) due to fair-value declines; indicates prior acquisition integration challenges and valuation deterioration
Source: AVNS 10-K Item 1A, Risk Factors; 'Any non-cash impairment of our long-lived assets' section and financial statements.
Anti-takeover provisions (preferred stock authority, supermajority removal, advance notice requirements) present; may limit shareholder activism
Source: AVNS 10-K; 'Certain provisions of our certificate of incorporation and by-laws...may make it difficult for stockholders to change the composition of our Board of Directors' section.

Disclosed initiatives

Board Oversight & Governance Structure

Company maintains Board of Directors with authority to approve strategic decisions, acquisitions, and risk management. Delaware incorporation with standard anti-takeover provisions.

Governance framework in place; board independence percentage not disclosed.
Cybersecurity & Data Governance

Company implemented Microsoft Co-Pilot, Enterprise ChatGPT, and Open Text AI solutions in early 2025 with security assessments. Enhanced AI policy with guardrails for data privacy, cybersecurity, and IP protection published.

Proactive risk mitigation for emerging technology governance.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Avanos Medical, Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Avanos Medical, Inc. in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)